Global Biosimilars Partnering Terms and Agreements Directory (2010 to 2020) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Biosimilars Partnering Terms and Agreements 2010 to 2020” report has been added to ResearchAndMarkets.com’s offering.

The Global Biosimilars Partnering Terms and Agreements 2010 to 2020 report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.

• Trends in Biosimilars partnering deals
• Disclosed headlines, upfronts, milestones and royalties by stage of development
• Biosimilars partnering contract documents
• Top Biosimilars deals by value

The Global Biosimilars Partnering Terms and Agreements report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Biosimilars partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Biosimilars technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual Biosimilars deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of Biosimilars dealmaking and business activities.

• Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Biosimilars dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.
• Chapter 3 provides a review of the leading Biosimilars deals since 2010. Deals are listed by headline value, signed by big pharma, most active Biosimilars dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
• Chapter 4 provides a comprehensive listing of the top 25 most active companies in Biosimilars dealmaking with a brief summary followed by a comprehensive listing of Biosimilars deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
• Chapter 5 provides a comprehensive and detailed review of Biosimilars partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
• Chapter 6 provides a comprehensive and detailed review of Biosimilars partnering deals signed and announced since Jan 2010. The chapter is organized by specific Biosimilars technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key Topics Covered:

Chapter 1 – Introduction

Chapter 2 – Trends in Biosimilars dealmaking

2.1. Introduction

2.2. Biosimilars partnering over the years

2.3. Most active Biosimilars dealmakers

2.4. Biosimilars partnering by deal type

2.5. Biosimilars partnering by therapy area

2.6. Biosimilars partnering by industry sector

2.7. Deal terms for Biosimilars partnering

2.7.1 Biosimilars partnering headline values

2.7.2 Biosimilars deal upfront payments

2.7.3 Biosimilars deal milestone payments

2.7.4 Biosimilars royalty rates

2.8. The anatomy of an Biosimilars deal

2.8. a. Case study 1: RRD International & Dipexium Pharmaceuticals

2.8.b. Case study 2: Hospira & Cempra Pharmaceutical

2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals

Chapter 3 – Leading Biosimilars deals

3.1. Introduction

3.2. Top Biosimilars deals by value

Chapter 4 – Most active Biosimilars dealmakers

4.1. Introduction

4.2. Most active Biosimilars dealmakers

4.3. Most active Biosimilars partnering company profiles

Chapter 5 – Biosimilars contracts dealmaking directory

5.1. Introduction

5.2. Biosimilars contracts dealmaking directory

Chapter 6 – Biosimilars dealmaking by technology type

Chapter 7 – Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

Companies Mentioned

• 3SBio
• Abbvie
• Abreos Biosciences
• Abzena
• Accord Healthcare
• Aceno Biotherapeutics
• AdAlta
• Aetos Biologics
• AffaMed Therapeutics
• Alteogen
• Altiora
• Alvogen
• Alvotech
• Amedica
• Amgen
• Amneal Pharmaceuticals
• Back-A-Line
• Bacterin International
• Baxter International
• Bio-Thera Solutions
• Biocon
• Bio Farma
• Biogen
• BioSciencesCorp
• C-Bridge Capital
• Dyadic International
• EirGenix
• EMD Millipore
• Epirus Biopharmaceuticals
• Epivax
• European Commission
• Ewopharma
• Fujifilm Kyowa Kirin Biologics
• Fuji Pharma
• Genentech
• Any Many More Companies!
  

For more information about this report visit https://www.researchandmarkets.com/r/evyzp4

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900